MAGEC1 and plasma cell myeloma: The aberrant re-expression of CTAs such as MAGE-C1/CT7 in various cancers, including multiple myeloma, makes them potential targets for immunotherapeutic interventions due to their restricted expression profile in normal tissues and their immunogenicity (6).